Pathogenicity of the MAGE family (Review)

Li, Sanyan; Shi, Xiang; Li, Jingping; Zhou, Xianrong

doi:10.3892/ol.2021.13105

Cited by 14 publications

(11 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since it was first isolated and cloned from melanoma in 1991, at least 13 subfamilies and 83 closely related gene members of the MAGE family have been found [ 11 ]. In general, MAGE is mainly manifested in the testicles and placenta, but it is widely and highly expressed in a variety of malignant tumors and has a certain correlation with tumorigenesis, development, drug resistance, and prognosis [ 12 ]. MAGE-A9 is one of the most studied members of the current MAGE family.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Clinical Value of MAGE-A9 Expressions in Cervical Cancer Tissues and PBMC

et al. 2022

Emergency Medicine International

View full text Add to dashboard Cite

Objective. The aim of this study is to explore the expressions and clinical significance of melanoma-associated antigen-A9 (MAGE-A9) in cervical cancer tissues and peripheral blood mononuclear cells (PBMC). Methods. 108 patients who were scheduled to undergo cervical conization or extensive hysterectomy between March 2019 and January 2021 due to cervical lesions were selected by convenient sampling. According to postoperative pathological results, the patients were divided into a cervical cancer group (n = 64) and cervical intraepithelial neoplasia (CIN) group (n = 44). The expression levels of MAGE-A9 mRNA in cervical lesion tissues and PBMC were detected by real-time fluorescence quantitative PCR, and the expression of MAGE-A9 protein in lesion tissues was detected by immunohistochemistry. The correlation between MAGE-A9 mRNA expressions in cancer tissues and PBMC and serum tumor markers in patients with cervical cancer and the relationship between MAGE-A9 protein expression in cancer tissues and clinicopathological characteristics were analyzed, and a receiver operating characteristic curve (ROC curve) was drawn to explore the diagnostic value of MAGE-A9 mRNA expressions in cancer tissues and PBMC on cervical cancer. Results. The expression levels of MAGE-A9 mRNA in cervical lesion tissues and PBMC in the cervical cancer group were significantly higher than those in the CIN group ( P < 0.05 ), and the levels of serum SCC-Ag, CA-125, and CEA were significantly higher than those in the CIN group ( P < 0.05 ). The positive rate of the MAGE-A9 protein expression in cervical lesion tissues in the cervical cancer group was significantly higher than that in the CIN group ( P < 0.05 ). The expression levels of MAGE-A9 mRNA in cancer tissues and PBMC of patients with cervical cancer were positively correlated with serum SCC-Ag, CA-125, and CEA ( P < 0.05 ). The positive rate of the MAGE-A9 protein expression in cervical cancer tissues was related to FIGO stage, tumor diameter, degree of differentiation, lymph node metastasis, and high-risk HPV infection ( P < 0.05 ) and was not correlated with age and pathological type ( P > 0.05 ). The areas under the ROC curves of MAGE-A9 mRNA in lesion tissue and MAGE-A9 mRNA in PBMC were 0.925 and 0.900 in the diagnosis of cervical cancer ( P < 0.05 ). Conclusion. The expressions of MAGE-A9 in cancer tissues and PBMC of patients with cervical cancer are upregulated, which is related to the levels of serum tumor markers and the progression of disease. MAGE-A9 is expected to become an important marker for the diagnosis of early cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of the Clinical Value of MAGE-A9 Expressions in Cervical Cancer Tissues and PBMC

et al. 2022

Emergency Medicine International

View full text Add to dashboard Cite

show abstract

“…The 40 most highly differentially regulated genes (including 20 upregulated and 20 downregulated) for each of the comparisons are presented in Tables 1 , 2 . Notably, this includes MAGE family oncogenes ( Li et al, 2021 ) A6/A3, A2B/A2 and A12, which were more highly expressed in PABC than in NPABC; and the CXCL family of chemokines ( Palacios-Arreola et al, 2014 ), which were upregulated (CXCL2) or downregulated (CXCL10, CXCL11) in PABC versus normal tissues.…”

Section: Resultsmentioning

confidence: 99%

Distinctive gene expression patterns in pregnancy-associated breast cancer

Wang

Peng

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Pregnancy-associated breast cancer (PABC) is diagnosed during pregnancy or within 1 year postpartum, but the unique aspects of its etiology and pathogenesis have not been fully elucidated. This study aimed to ascertain the molecular mechanisms of PABC to facilitate diagnosis and therapeutic development. The Limma package was used to characterize the differentially expressed genes in PABC as compared to non-pregnancy-associated breast cancer (NPABC) and normal breast tissue. A total of 871 dysregulated genes were identified in the PABC versus NPABC groups and 917 in the PABC versus normal groups, with notable differences in the expression of MAGE and CXCL family genes. The dysregulated genes between the PABC and normal groups were mainly associated with signal transduction and immune response, while Kyoto Encyclopedia of Genes and Genomes analysis revealed that the dysregulated genes were enriched in immune-related pathways, including the major histocompatibility complex (MHC) class II protein complex, the type I interferon signaling pathway, regulation of α-β T-cell proliferation, and the T-cell apoptotic process. Through protein-protein interaction network construction, CD44 and BRCA1 were identified as prominent hub genes with differential expression in PABC versus NPABC. Furthermore, a cluster with eleven hub genes was identified in PABC versus normal adjacent tissues, of which the expression of EGFR, IGF1, PTGS2, FGF1, CAV1, and PLCB1 were verified to be differentially expressed in an independent cohort of PABC patients. Notably, IGF1, PTGS2, and FGF1 were demonstrated to be significantly related to patient prognosis. Our study reveals a distinctive gene expression pattern in PABC and suggests that IGF1, PTGS2, and FGF1 might serve as biomarkers for diagnosis and prognosis of PABC.

show abstract

“…7 The melanoma antigen gene (MAGE) protein family is a large, highly conserved group of proteins with a common MAGE homology domain. 8 MAGE-A is a CTA and a Type I MAGE, which in humans includes members of the MAGE-A, MAGE-B, and MAGE-C subfamilies clustered on the X chromosome. 9 Although the expression of many MAGE proteins is restricted to reproductive tissues similar to NY-ESO, they have been reported to be aberrantly expressed in various cancers.…”

Section: Introductionmentioning

confidence: 99%

“…Among MAGEs, MAGE-A4 is widely expressed in many tumor types, including esophageal (60%), ovarian (47%), lung (19-35%), colorectal (22%), and breast (13%) cancers. 8,9 The tumor suppressor gene TP53 and its protein product p53 are known to play a major role in cancer progression and suppression, as they are mutated in several cancers. 10 p53 is a transcription factor that promotes the expression of proteins responding to cellular stresses such as hypoxia, viral infection, metabolic stress, endoplasmic reticulum stress, and oxidative stress.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma

et al. 2022

View full text Add to dashboard Cite

The cancer/testis antigens (CTAs), New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma antigen gene (MAGE)-A4 are normally restricted to male germ cells but are aberrantly expressed in several cancers. Considering the limited information regarding their significance in osteosarcoma (OS), the purpose of this study was to determine the clinical significance of NY-ESO-1 and MAGE-A4 expression in OS. Nine patients with OS treated at Kindai University Hospital were included in the study. The median age was 27 years, and median follow-up period was 40 months. The specimens obtained at the time of biopsy were used to perform immunostaining for NY-ESO, MAGE-A4, p53, and Ki-67. The positive cell rates and positive case rates of NY-ESO, MAGE-A4, p53, and Ki-67 were calculated. The correlation between the positive cell rate of immunohistochemical markers was also calculated. The correlation between the positive cell rate of NY-ESO-1 or MAGE-A4 and tumor size or maximum standardized uptake (SUV-max) was also determined. The positive cell rates of NY-ESO-1 or MAGE-A4 in continuous disease-free (CDF) cases were also compared with those in alive with disease (AWD) or dead of disease (DOD) cases. The average positive cell rates of NY-ESO, MAGEA4, p53, and Ki-67 were 71.7%, 85.1%, 16.2%, and 14.7%, and their positive case rates were 33.3%, 100%, 44.4%, and 100%, respectively. The positivity rates of NY-ESO-1 and p53 were strongly correlated, whereas those of NY-ESO-1 and Ki-67 were moderately correlated. The MAGE-A4 and p53 positivity rates and the MAGE-A4 and Ki-67 positive cell rates were both strongly correlated. The NY-ESO-1 and MAGE-A4 positivity rates were moderately correlated. The positive correlation between the NY-ESO-1 positive cell rate and tumor size was medium, and that between the MAGE-A4 positivity rate and SUV-max was very strong. There was no significant difference in the positive cell rates of NY-ESO-1 or MAGE-A4 between CDF cases and AWD or DOD cases. Overall, our results suggest that NY-ESO-1 and MAGE-A4 may be involved in the aggressiveness of OS.

show abstract

Pathogenicity of the MAGE family (Review)

Cited by 14 publications

References 80 publications

Analysis of the Clinical Value of MAGE-A9 Expressions in Cervical Cancer Tissues and PBMC

Analysis of the Clinical Value of MAGE-A9 Expressions in Cervical Cancer Tissues and PBMC

Distinctive gene expression patterns in pregnancy-associated breast cancer

Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma

Contact Info

Product

Resources

About